BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyasaka A, Yoshida Y, Yoshida T, Murakami A, Abe K, Ohuchi K, Kawakami T, Watanabe D, Hoshino T, Sawara K, Takikawa Y. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1. Intern Med 2018;57:2807-12. [PMID: 29780135 DOI: 10.2169/internalmedicine.0810-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, Van Frank T, Guerrero R, Hinojosa K, Christensen K, Pedicone LD, Alkhouri N, Wells J, Landaverde C, Rodas F, Lawitz E, Poordad F. Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance. Medicine (Baltimore) 2019;98:e16254. [PMID: 31261592 DOI: 10.1097/MD.0000000000016254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Tatar B, Köse Ş, Ergun NC, Turken M, Onlen Y, Yılmaz Y, Akhan S. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience. Rev Assoc Med Bras (1992) 2019;65:1470-5. [PMID: 31994628 DOI: 10.1590/1806-9282.65.12.1470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]